The DEA Learned From 2016 — This Time It's Only Banning Half the Plant

John Koch spent years using heroin, then fentanyl, before he got into recovery. Now he answers the phone at Community Medical Services, an opioid treatment provider with clinics across Arizona, and lately the calls have a pattern: gas station gummies, a foil strip from a smoke shop counter, a crash that looks exactly like the one he used to live through himself. “Since Friday, we’ve seen three,” he told AZFamily in April — three new patients at his clinic alone, part of what he counted as 29 cases statewide tied to a compound most of them couldn’t pronounce: 7-hydroxymitragynine, sold as “7-OH.”

A reporter walked into an Arizona vape shop that same month and bought a 7-OH product for $20, no ID required, despite state law requiring buyers to be 18. The addiction medicine physician who reviewed the purchase, Dr. Michel Sucher, put it plainly: users “can become addicted to it like you can become addicted to heroin or fentanyl or morphine,” and an overdose “can literally end up stopping breathing.” That’s not a metaphor. 7-OH is a concentrated opioid — a compound that locks onto the same brain receptors as morphine and fentanyl, producing pain relief, euphoria, and the same physical dependence — extracted and boosted far beyond what occurs naturally in the kratom leaf it’s named after.

On July 1, 2026, the DEA filed Notices of Intent to temporarily place 7-OH and three related lab-made compounds — mitragynine pseudoindoxyl, MGM-15, and MGM-16 — into Schedule I, the legal category reserved for drugs the federal government says have no accepted medical use and a high potential for abuse, the same category as heroin. The rule targets products above a 0.05% concentration by weight: the gummies, tablets, and dissolvable strips sold at gas stations and smoke shops. It does not touch the dried leaf or powder that millions of Americans already use.

That distinction is the whole story, and it’s worth saying plainly:

A federal agency finally figured out how to ban the poison without banning the plant — but a two-year emergency order is not a policy, and the people it’s supposed to protect still have nowhere legal to land when it expires.

A gas station transaction, a clinic phone that won’t stop ringing

Koch’s math — three new patients in a weekend, 29 across Arizona — is a symptom, not the disease. The products he’s describing didn’t exist in most states two years ago. They exist now because someone figured out how to strip mitragynine, kratom’s primary and comparatively mild natural alkaloid, and convert or concentrate it into 7-OH at levels the plant itself would never produce on its own — turning a leaf some people brew as tea into something with, by some lab estimates, ten times the potency of morphine at the same receptor. It gets marketed with the same packaging language as a supplement: relaxation, focus, energy. It gets sold next to energy shots and rolling papers, with none of the counter conversation a pharmacist would have about an opioid prescription.

If you’re reading this in recovery, or still using, you already know the gap this fills. Maybe you’ve used kratom leaf to get through a Suboxone taper, or to manage pain after your prescription ran out and nobody would write another one. Maybe you tried a gas station 7-OH gummy because it was legal, cheap, and didn’t require explaining yourself to anyone. None of that makes you reckless. It makes you someone navigating a system that’s left you without a good option — and it’s exactly why the difference between kratom leaf and concentrated 7-OH is not a technicality. It’s the difference between a plant with a wide margin of safety and an unregulated opioid sold with no dosing standard, no purity testing, and no age check that anyone actually enforces.

The ban that only bans half the plant

DEA Administrator Terrance Cole framed the action narrowly: “Today’s action targets highly concentrated, synthetic 7-OH products, which pose a growing threat to public safety and health,” he said in the agency’s release. HHS Secretary Robert F. Kennedy Jr. was blunter, calling the compounds “dangerous opioids that fuel addiction and put American lives at risk.” Under the Controlled Substances Act’s emergency scheduling authority — a power that lets the DEA bypass the years-long standard rulemaking process and impose a ban for up to two years when it decides a substance poses an “imminent hazard” — the rule becomes final when it publishes in the Federal Register on July 6, 2026, and takes effect in early August.

Two industry camps read the same notice in opposite directions. The American Kratom Association, which has spent a decade lobbying to keep whole-leaf kratom legal, welcomed it outright. “This DEA action should end the debate,” the group’s senior policy fellow, Mac Haddow, said in a statement. “Chemically manipulated 7-OH opioids are not kratom.” The 7-HOPE Alliance, which represents makers of concentrated 7-OH extracts, said it plans to fight the scheduling, arguing that 7-OH is already lawful under federal food and drug law and citing researchers who say there are no confirmed 7-OH overdose deaths in national poison-control data. Both of those things can be true at once — no confirmed deaths yet, and a compound potent enough that an addiction physician in Phoenix is watching new dependence cases walk in weekly. Absence of a body count is not the same as absence of harm, and Pain News Network’s reporting on the notice makes clear the DEA is acting on a trend line, not a final tally.

“This DEA action should end the debate,” the group’s senior policy fellow, Mac Haddow, said in a statement.

What matters for anyone using kratom or 7-OH right now is what the rule doesn’t touch: raw leaf, traditional powder, and low-concentration products stay outside Schedule I. You do not lose access to kratom tea. You lose access — starting in August, for up to two years, pending whatever comes next — to the synthetic, high-potency products that look like candy and act like an opioid.

2016: the year the DEA blinked, and why that matters now

This is not the DEA’s first run at this plant. In August 2016, the agency announced its intent to emergency-schedule not just concentrated extracts but mitragynine and 7-hydroxymitragynine wholesale — meaning the entire kratom plant, leaf and all, the tea along with the gummy. The backlash was immediate and it was large. Kratom users, many of them managing chronic pain or using the leaf to stay off opioids without any other option available to them, protested outside the White House. More than 140,000 people signed a petition demanding the DEA reverse course. Fifty-one members of Congress sent letters opposing the ban, arguing the agency had moved without adequately weighing kratom’s use as a harm-reduction tool. Two months later, in October 2016, the DEA did something it has done almost nowhere else in its history: it withdrew the notice. The agency’s own Federal Register filing cites the volume of public comment and requests that the agency weigh that input before acting further — bureaucratic language for what was, functionally, a retreat under public pressure.

Ten years is not a coincidence-length gap. It’s roughly how long it took a synthetic-adjacent product to emerge that could plausibly justify a narrower version of the same fight — and it’s clear DEA leadership remembers how the last one went. This time the notice does not touch the leaf that got 140,000 people to sign a petition and 51 members of Congress to write letters. It targets the gas station gummy, not the tea. That is the agency learning something. Whether it learned the right lesson — that the plant and the drug made from stripping it aren’t the same thing — or just the tactical lesson that whole-plant bans generate backlash it doesn’t want to manage twice, is a fair question. Either way, people who rely on kratom leaf are not the target this time. That’s worth saying clearly, because the last time this happened, the uncertainty itself was what hurt — pharmacies and vendors pulled products off shelves for months in 2016 out of fear of a ban that never actually took effect, cutting people off from something they depended on before the government had even finished deciding.

Why the line is real — and why a two-year clock isn’t a plan

Here’s the case for this ban: concentrated 7-OH is functionally a new opioid, sold with none of the infrastructure — dosing information, purity testing, prescriber oversight — that even a bad opioid prescription comes with. SAMHSA’s National Survey on Drug Use and Health estimates roughly 1.6 to 1.8 million Americans use kratom in a given year, most of them using leaf or powder for pain, energy, or to manage withdrawal — not the synthetic extracts this rule targets. Folding synthetic 7-OH into that same conversation, the way the 2016 notice did, would have criminalized the coping mechanism of people who were never the problem. This rule doesn’t do that, and it deserves credit for the restraint.

Here’s the case against stopping there: emergency scheduling lasts up to two years. It is, by design, a stopgap — a tool for stopping the bleeding while the DEA and FDA figure out a permanent classification, and nothing in this notice commits either agency to finishing that work before the clock runs out. The 2016 episode shows what happens in the gap between “temporary” and “settled”: confusion, inconsistent enforcement, vendors pulling products preemptively, and a black market that doesn’t wait for Schedule I paperwork to catch up. Making concentrated 7-OH illegal doesn’t make the demand for it disappear — it makes John Koch’s phone ring more, not less, as the current unregulated supply gets replaced by an even less regulated one. A ban on the product is not treatment for the people who were using it to avoid something worse. Nothing in this DEA notice funds a single new bed, a single new prescriber, or a single hour of the counseling that actually helps someone taper off an opioid-like compound safely.

A ban on the product is not treatment for the people who were using it to avoid something worse.

If you’re using 7-OH right now and this scheduling has you worried about what happens in August, that’s a real thing to sit with, not something to white-knuckle alone. Whole-leaf kratom is still legal and still on the shelf — this rule was written specifically to leave it there. And SAMHSA’s National Helpline, 1-800-662-4357, is free, confidential, staffed around the clock, and doesn’t require you to explain the legal status of anything you’ve taken to get help figuring out what’s next. That’s not policy trivia. That’s still yours, tonight, regardless of what the Federal Register says on July 6.

The plant survives. The people using it deserve more than a temporary answer.

The DEA did something in this notice it refused to do in 2016: it looked at a plant and a drug made by manipulating that plant, and it treated them as different things. That’s not nothing. It’s the difference between a rule that protects John Koch’s patients from a gas station product with an unknown dose and a rule that would have taken away the tea someone’s been using for three years to stay off the pills that got them into treatment in the first place.

But drawing the right line and finishing the job are two different accomplishments, and the DEA has only done the first one. A two-year emergency window with no funded off-ramp is a bet that the agency, or Congress, or the FDA will do the harder work of permanent, evidence-based classification before the clock runs out — the same bet that, a decade ago, quietly expired into confusion until public pressure forced a reversal. Koch didn’t stop answering the phone because the DEA issued a press release. He’ll still be answering it in August, and in 2028, whatever Schedule 7-OH lands in by then. The plant isn’t the threat here. The absence of anything built to replace what people were using it for is.